TTY Biopharm Company Limited (4105.TWO)
Taipei Exchange · TWD · Healthcare · Drug Manufacturers - Specialty & Generic
NT$80.00 (-0.74%) as of
Key statistics
- Market cap
- 19.89B
- P/E (TTM)
- 11.49
- Forward P/E
- 10.83
- EPS (TTM)
- 6.96
- Dividend yield
- 5.58%
- 52-week range
- 71.60 – 87.00
- Beta
- 0.09
- Revenue (TTM)
- 6.65B
- Profit margin
- 26.04%
- Analyst target
- NT$92.00
- Volume
- 564.48k
About TTY Biopharm Company Limited
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan, the United States, and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, Other Business Unit, and Re-investment Business Unit segments. It offers oncology drugs for the treatment of anticancer and adjunctive therapies under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Yondelis, Pemazyre, Pulmivex, Xpovio, Minjuvi, and Fustron names. The company also provides anti-infective drugs and anesthetics to treat second-line antimicrobial agents, influenza, and anesthetics under the Brosym, Bobimixyn, Colimycin, Cubicin, Lipo-AB, Flusine, Maxtam, Metacin, Flucelvax, Fluad, and Byfavo names; and healthcare products for the treatment of gastrointestinal health, bone health, and metabolic regulation under the Algitab, Alginos, Bio-Cal Plus, Sulfin names. In addition, it offers contract development and manufacturing (CDMO) services. The company was incorporated in 1960 and is headquartered in Taipei, Taiwan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Taipei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.